Psilo Scientific makes Health Canada’s list of licensed psilocybin producers

The company is a subsidiary of Burnaby-based psychedelics venture Filament Health Corp.

The psychedelics company grows high-potency magic mushrooms at its Metro Vancouver facility. Photo by Filament.

0

Health Canada has included a Metro Vancouver company in its list of licensed psilocybin producers.

Psilocybin is the psychoactive substance derived from so-called magic mushrooms.

Studies suggest that the psychedelic compound is effective in treating a range of mental-health conditions.

Filament Health Corp., a Burnaby-based natural psychedelics drug company, has announced that its wholly-owned subsidiary, Psilo Scientific Ltd., made Health Canada’s list.

This means that scientific researchers and health care practitioners will have the option to choose Psilo Scientific for access to psilocybin.

The development comes less than a month after Health Canada amended its Special Access Program or SAP to allow health care professionals to request non-marketed drugs.

These drugs, which include restricted substances like psychedelics, are intended to treat patients with serious or life-threatening conditions.

Access to these drugs has been restricted since 2013.

The amended SAP came into effect on January 5, 2022.

“Our inclusion in this list will aid us in adding to our growing number of partnerships in the Canadian psychedelic ecosystem,” Filament CEO Benjamin Lightburn said in a media release Wednesday (January 26).

In a previous media release, Lightburn commended Health Canada for restoring access to restricted drugs through the SAP.

“Clinical trials remain the best mechanism for access to psilocybin, psilocin, and other restricted psychedelic drugs before they are approved,” Lightburn said in the January 5 release, when the new regulations took effect.

Around summer last year, Filament revealed that Psilo Scientifc has grown its 20th cultivar of high-potency psilocybin mushrooms at its Metro Vancouve facility.

The company owns a 3,500- square-foot research and development site.

Follow Carlito Pablo on Twitter at @carlitopablo

Leave your opinion for the editor...We read everything!

Your email address will not be published.